Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer
Phase 1 Recruiting
46 enrolled
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Phase 3 Recruiting
158 enrolled
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Phase 2 Recruiting
150 enrolled
(NeoScorch HN)
Phase 2 Recruiting
75 enrolled
TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
Phase 1 Recruiting
40 enrolled
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Phase 2 Recruiting
189 enrolled
A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)
Phase 2 Recruiting
40 enrolled
Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study
Phase 2 Recruiting
174 enrolled
Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
Phase 2 Recruiting
28 enrolled
CONFIRM
Phase NA Recruiting
70 enrolled
SMART - 1_1
Phase NA Recruiting
105 enrolled
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
Phase 2 Recruiting
98 enrolled
iCaRe2
Recruiting
999,999 enrolled
Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"
Phase NA Recruiting
590 enrolled
ENDURE
Phase NA Recruiting
532 enrolled
Clinical Treatments in Specialized Diseases of Laryngeal Carcinoma (LC) and Hypopharyngeal Carcinoma (HPC)
Recruiting
1,000 enrolled
G-FORCE
Phase NA Recruiting
67 enrolled
DETERMINE
Phase 2/3 Recruiting
30 enrolled
HexAgon-HN
Phase 2/3 Recruiting
410 enrolled
Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer
Recruiting
471 enrolled
VoiceS
Phase NA Recruiting
34 enrolled
Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
Recruiting
700 enrolled
TraveraRTGx
Recruiting
200 enrolled
VoiceDetect
Recruiting
100 enrolled
Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation
Phase NA Recruiting
118 enrolled
SENIOR
Recruiting
1,500 enrolled
EMST in Patients Undergoing CRT for HNCA
Phase NA Recruiting
30 enrolled
SBRT Followed by Chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin for Larynx Preservation in Patients with Locally Regionally Advanced Squamous Cell Carcinoma of the Larynx and Hypopharynx
Phase 2 Recruiting
35 enrolled
ELOS
Phase 2 Recruiting
140 enrolled
AI Models to Predict Thyroid Cartilage Invasion in Laryngeal Carcinoma
Recruiting
400 enrolled
Study of the Risk of Pharyngocutaneous Fistula in a Population of Patients Undergoing Total Laryngectomy and Creation of a Score for Pre-operative Risk Stratification.
Recruiting
500 enrolled
Neoadjuvant Chemoimmunotherapy Followed By Radiation Or Organ Preservation Surgery In Laryngeal/Hypopharyngeal Cancer
Phase 2 Recruiting
82 enrolled
iCHRTL
Phase NA Recruiting
40 enrolled
ImmunBio-KHT
Recruiting
1,100 enrolled
GRAAL
Phase NA Recruiting
4 enrolled